PMID- 34149916 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210907 IS - 1837-9664 (Print) IS - 1837-9664 (Electronic) IS - 1837-9664 (Linking) VI - 12 IP - 15 DP - 2021 TI - Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres(R) microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study. PG - 4522-4529 LID - 10.7150/jca.54650 [doi] AB - Objective: To prospectively evaluate the safety and therapeutic effectiveness of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) with CalliSpheres(R) microsphere (CSM) for the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), and to analyze the prognostic factors. Method: Between November 2015 and November 2017, consecutive 58 HCC patients with PVTT who received DEB-TACE with CSM treatment were prospectively enrolled in this study. The demographic characteristics, adverse events (AEs) and treatment response were collected. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method. Univariate and multivariate Cox regression analyses were performed to determine the independent factors correlated with OS. Results: The objective response rate (ORR) was 79.3% in terms of tumors and 44.8% in thrombi. The median PFS and OS of patients were 5.0 months and 9.0 months respectively. The cumulative survival rate at 3-, 6-, 9-, 12-, 18- and 24-month were 94.8%, 72.4%, 53.4%, 41.4%, 22.4% and 19.0%, respectively. In a stepwise multivariate Cox proportional hazards model, the higher Child-Pugh classification (HR=2.279; 95%CI, 1.042-4.985, p = 0.039) and tumor burden (p = 0.008) were the significant predictors of poorer OS after adjustment for known risk factors. The most common clinical AEs were postembolization syndrome (PES) and the most prevalent laboratory toxicity was transient liver function damage. Conclusion: DEB-TACE with CSM is safe and well-tolerated in HCC patients with PVTT, and reveals a favorable preliminary clinical outcome. The higher Child-Pugh classification and liver tumor burden are independent prognostic factors associated with poor survival for HCC patients with PVTT treated by DEB-TACE with CSM. CI - (c) The author(s). FAU - Zhou, Tan-Yang AU - Zhou TY AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Chen, Sheng-Qun AU - Chen SQ AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou 310003, Zhejiang Province, China. FAU - Wang, Hong-Liang AU - Wang HL AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Weng, Sheng-Ming AU - Weng SM AD - Department of Radiology, Jingning County People's Hospital, Lishui, Zhejiang Province, China. FAU - Zhou, Guan-Hui AU - Zhou GH AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Zhang, Yue-Lin AU - Zhang YL AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Nie, Chun-Hui AU - Nie CH AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Zhu, Tong-Yin AU - Zhu TY AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Wang, Bao-Quan AU - Wang BQ AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Yu, Zi-Niu AU - Yu ZN AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Jing, Li AU - Jing L AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. FAU - Chen, Feng AU - Chen F AD - Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Sun, Jun-Hui AU - Sun JH AD - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. AD - Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. AD - Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou 310003, Zhejiang Province, China. LA - eng PT - Journal Article DEP - 20210601 PL - Australia TA - J Cancer JT - Journal of Cancer JID - 101535920 PMC - PMC8210571 OTO - NOTNLM OT - Chemoembolization OT - Hepatocellular carcinoma OT - Microspheres OT - Prognosis OT - Therapeutic COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2021/06/22 06:00 MHDA- 2021/06/22 06:01 PMCR- 2021/01/01 CRDT- 2021/06/21 05:53 PHST- 2020/10/18 00:00 [received] PHST- 2021/05/18 00:00 [accepted] PHST- 2021/06/21 05:53 [entrez] PHST- 2021/06/22 06:00 [pubmed] PHST- 2021/06/22 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - jcav12p4522 [pii] AID - 10.7150/jca.54650 [doi] PST - epublish SO - J Cancer. 2021 Jun 1;12(15):4522-4529. doi: 10.7150/jca.54650. eCollection 2021.